CoChat
Sign Up
Cited by 244Parkinson's Disease Mechanisms and TreatmentsAutophagy in Disease and TherapyLysosomal Storage Disorders Research

The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.

Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression

Henry, Anastasia G., Aghamohammadzadeh, Soheil, Samaroo, Harry, Chen, Yi, Mou, Kewa, Needle, Elie, Hirst, Warren D.·2015·Human Molecular Genetics
DOI 10.1093/hmg/ddv314
Open this paper in CoChat — free account

Abstract

Lysosomal dysfunction plays a central role in the pathogenesis of several neurodegenerative disorders, including Parkinson's disease (PD). Several genes linked to genetic forms of PD, including leucine-rich repeat kinase 2 (LRRK2), functionally converge on the lysosomal system. While mutations in LRRK2 are commonly associated with autosomal-dominant PD, the physiological and pathological functions of this kinase remain poorly understood. Here, we demonstrate that LRRK2 regulates lysosome size, number and function in astrocytes, which endogenously express high levels of LRRK2. Expression of LRRK2 G2019S, the most common pathological mutation, produces enlarged lysosomes and diminishes the lysosomal capacity of these cells. Enlarged lysosomes appears to be a common phenotype associated with pathogenic LRRK2 mutations, as we also observed this effect in cells expressing other LRRK2 mutations; R1441C or Y1699C. The lysosomal defects associated with these mutations are dependent on both the catalytic activity of the kinase and autophosphorylation of LRRK2 at serine 1292. Further, we demonstrate that blocking LRRK2's kinase activity, with the potent and selective inhibitor PF-06447475, rescues the observed defects in lysosomal morphology and function. The present study also establishes that G2019S mutation leads to a reduction in lysosomal pH and increased expression of the lysosomal ATPase ATP13A2, a gene linked to a parkinsonian syndrome (Kufor-Rakeb syndrome), in brain samples from mouse and human LRRK2 G2019S carriers. Together, these results demonstrate that PD-associated LRRK2 mutations perturb lysosome function in a kinase-dependent manner, highlighting the therapeutic promise of LRRK2 kinase inhibitors in the treatment of PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddv314

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Cited by

Sorted by citations

Items 101–200 of 244

Related

See all

Metadata

Authors
Henry, A. G., Aghamohammadzadeh, S., Samaroo, H., Chen, Y., Mou, K., Needle, E., & Hirst, W. D.
Affiliations
Pfizer (United States) (US)
Corresponding author
Hirst, Warren D.
ORCID
Venue
Human Molecular Genetics
Publisher
Oxford University Press (OUP)
Published
2015-08-06
Volume
24
Issue
21
Pages
6013-6028
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
DOI
10.1093/hmg/ddv314
OpenAlex
W2100867992
Cited by
235
References
90
Citations by year
2026: 19 · 2025: 25 · 2024: 21 · 2023: 24 · 2022: 24 · 2021: 28 · 2020: 32 · 2019: 16 · 2018: 20 · 2017: 15 · 2016: 8 · 2015: 2
FWCI
10.58
Type
journal article
Language
en
Open access
closed
Locations
  • Human Molecular Genetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of California, Davis
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
LRRK2, Parkinson's disease, lysosomal dysfunction, LRRK2 kinase activity, LRRK2 G2019S mutation, autophosphorylation, ATP13A2, lysosomal pH, astrocytes, Kufor-Rakeb syndrome, LRRK2 inhibitors
MeSH terms
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Adenosine Triphosphatases, Animals, Astrocytes, Brain, Cells, Cultured, Proton-Translocating ATPases, Humans, Hydrogen-Ion Concentration, Lysosomes, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Parkinson Disease, Phenotype, Phosphorylation, Up-Regulation, Protein Serine-Threonine Kinases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review